VANCOUVER and CARLSBAD, CA, June 2 /CNW/ - OncoGenex Technologies Inc.
and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced preliminary data
from a Phase II clinical trial of OGX-011 in combination with docetaxel and
prednisone in patients with metastatic hormone refractory prostate cancer
(HRPC). Data were presented by Dr. Kim Chi, Study Chair and a medical
oncologist at BC Cancer Agency - Vancouver Centre, representing the National
Cancer Institute of Canada - Clinical Trials Group at the Annual Meeting of
the American Society of Clinical Oncology (ASCO) in Chicago.
Eighty-one patients with metastatic or locally recurrent prostate cancer
refractory to hormone therapy were randomized to one of two treatment arms to
receive either 640 mg OGX-011 per week in combination with docetaxel and
prednisone or docetaxel and prednisone alone. As of May 14, 2007 all 81
patients had been followed for a minimum of 4.8 months. Currently, 22 percent
of patients are still receiving study treatment and all patients continue to
Summary of Preliminary Results from this Ongoing Study:
- The median duration of progression-free survival was 7.3 months in
patients who received OGX-011 plus docetaxel and 5.8 months in
patients who received docetaxel.
- Disease progression occurred in fewer patients who received OGX-011
- Progressive measurable disease as the best response occurred in
4 percent of patients in the OGX-011 plus docetaxel arm and in
22 percent of patients in the docetaxel arm.
- PSA progression as the best response occurred in no patients in
the OGX-011 plus docetaxel arm and in 10 percent of patients in
the docetaxel arm.
- While response rates for both measurable disease and PSA assessments
in the study arms were similar, disease stabilization, by both
assessments, occurred in more patients in the OGX-011 plus docetaxel
- Stable measurable disease as the best response occurred in
73 percent of patients in the OGX-011 plus docetaxel arm (median
duration 9.7 months) and in 52 percent of patients in the
docetaxel arm (median duration 7.6 months).
- PSA stabilization (i.e. PSA non-response/non-progression)
occurred in 45 percent of patients in the OGX-011 plus docetaxel
arm and in 32 percent of patients in the docetaxel arm.
- The primary endpoint of PSA response was seen in 20 of 40 patients
who received OGX-011 plus docetaxel. This number of responses met the
criterion for declaring this combination of interest to explore
further. PSA response was seen in 21 of 40 patients who received
docetaxel, indicating this arm also met the same criterion.
"These preliminary data support the continued development of OGX-011 in
prostate cancer," said Dr. Chi, medical oncologist at the Vancouver Prostate
Center and the BC Cancer Agency, and the lead investigator in the study.
"Follow-up evaluation of all patients at the completion of study treatment and
at six months post treatment will provide additional information that will
allow us to conduct further assessment of the therapeutic activity of
"Data from a previously conducted Phase I study in prostate cancer
suggest that OGX-011 can effectively regulate its target, clusterin, a protein
expressed by tumor cells and associated with treatment resistance," said Scott
Cormack, president and CEO of OncoGenex. "We are encouraged with the
preliminary results in patients who received OGX-011, particularly the high
rates of disease stabilization in both assessments of measurable disease and
PSA. These data support our further evaluation of the therapeutic potential of
OGX-011 in prostate cancer."
Study Design and Safety Results:
The study was designed as a non-comparative Phase II study. Any
differences observed between study arms were not designed to be subject to
statistical analyses but instead, were intended to guide future development of
OGX-011 and to provide preliminary guidance regarding activity and
tolerability. Patients were randomized to one of two treatment arms to receive
either 640 mg per week of OGX-011 by intravenous infusion in combination with
docetaxel and prednisone or docetaxel and prednisone alone.
The median number of cycles of chemotherapy administered was 8 in
patients who received OGX-011 plus docetaxel (range 1-10) and 6 in patients
who received docetaxel (range 1-10).
The investigators concluded that treatment with OGX-011 was well
tolerated. All 81 treated patients were evaluable for non-hematological and
hematological adverse events. The following events (all grade 1 or 2) were
documented more commonly in patients given OGX-011 plus prednisone and
docetaxel than patients given prednisone and docetaxel alone: fever
(50 percent and 15 percent), rigors/chills (60 percent and 7 percent),
sweating (25 percent and 12 percent), sensory neuropathy (70 percent and 49
percent) and limb edema (38 percent and 27 percent). The majority of patients
experienced granulocytopenia and neutropenia, with similar frequency and
magnitude in each arm. Grade 3/4 lymphopenia was more common in patients
receiving OGX-011 plus docetaxel (53 percent) than in patients who received
docetaxel (20 percent). In general, the toxicities were consistent for the
adverse event profile for docetaxel and prednisone. There were 11 serious
adverse events (SAEs) reported for each study arm.
The study was supported by a grant from the Canadian Cancer Society
through the National Cancer Institute of Canada and coordinated by the
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) based at
Queen's University in Kingston, Ontario, which is also funded by the Canadian
Cancer Society. The study was further supported by OncoGenex, Isis and an
unrestricted grant from sanofi-aventis.
OGX-011 is designed to specifically inhibit the production of the
cell-survival protein, clusterin. Clusterin production is associated with
treatment resistance in many cancers and in response to various cancer
treatments, including hormone ablation therapy, chemotherapy and radiation
therapy. Preclinical studies have shown that inhibition of clusterin can
disable the tumor cell's adaptive defences, render the tumor cells susceptible
to attack with a variety of cancer therapies, including chemotherapy, and
facilitate tumor-cell death. OncoGenex and Isis are collaborating on
development of OGX-011, which is the subject of five ongoing Phase II studies
evaluating the safety and activity of OGX-011 in patients with prostate
cancer, non-small cell lung cancer and breast cancer.
OncoGenex is committed to the development and commercialization of new
cancer therapies that address treatment resistance in cancer patients.
OncoGenex currently has three product candidates in development: OGX-011,
OGX-427 and OGX-225. These product candidates are designed to selectively
inhibit the production of proteins that are associated with treatment
resistance and that are over-produced in response to a variety of cancer
treatments. OncoGenex' aim in targeting these particular proteins is to
disable the tumor cells' adaptive defenses, render the tumor cells susceptible
to attack with a variety of cancer therapies including chemotherapy, and
facilitate tumor cell death. More information on OncoGenex and the company's
pipeline is available at www.oncogenex.ca.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 17 drugs
in development. Isis' drug development programs are focused on treating
cardiovascular and metabolic diseases. Isis' partners are developing drugs for
cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis'
wholly owned subsidiary, is developing and commercializing the Ibis T5000
Biosensor System, a revolutionary system to identify infectious organisms. As
an innovator in RNA-based drug discovery and development, Isis is the owner or
exclusive licensee of over 1,500 issued patents worldwide. Additional
information about Isis is available at www.isispharm.com.
Isis Pharmaceuticals, Inc. Forward-Looking Statement
This press release includes forward-looking statements regarding the
development, activity, therapeutic potential and safety of OGX-011 in treating
cancer. Any statement describing Isis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement and should
be considered an at-risk statement, including those statements that are
described as Isis' goals. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective for use as
human therapeutics, and in the endeavor of building a business around such
products. Isis' forward-looking statements also involve assumptions that, if
they never materialize or prove correct, could cause its results to differ
materially from those expressed or implied by such forward-looking statements.
Although Isis' forward-looking statements reflect the good faith judgment of
its management, these statements are based only on facts and factors currently
known by Isis. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form 10-K for the
year ended December 31, 2006, and its quarterly report on Form 10-Q for the
quarter ended March 31, 2007, which are on file with the SEC. Copies of this
and other documents are available from the Company.
Isis Pharmaceuticals, Ibis Biosciences and Ibis T5000 are registered
trademarks or trademarks of Isis Pharmaceuticals, Inc.
For further information:
For further information: OncoGenex Contact: Scott Cormack, President &
CEO, (604) 630-5400; OncoGenex Media Contact: Rachel Lipsitz, Porter Novelli
Life Sciences, (858) 449-9575; Isis Contact: Kate Corcoran, Vice President,
Corporate Development, (760) 603-2712